- Home
- FDMT
FDMT
4D Molecular Therapeutics Inc.
as 03-27-2025 3:36pm EST
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $35.00 | AVG Volume (30 days): | 727.0K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $34.20 | Next Earning Date: | 05-08-2025 |
| Revenue: | $37,000 | Revenue Growth: | -99.82% |
| Revenue Growth (this year): | 11029.73% | Revenue Growth (next year): | 44.15% |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 hours ago
4DMT to Participate in Upcoming Investor Conferences
GlobeNewswire
18 days ago
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
TipRanks
24 days ago
4D Molecular price target lowered to $35 from $39 at RBC Capital
MT Newswires
24 days ago
Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating
MT Newswires
25 days ago
RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk
Simply Wall St.
a month ago
4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations
GlobeNewswire
a month ago
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Simply Wall St.
a month ago
Spotlight On February 2025's Promising Penny Stocks
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.